PRospective Evaluation of Interstitial Lung DIsease Progression With Quantitative CT
Launched by UNIVERSITY OF EXETER · Nov 1, 2022
Trial Information
Current as of June 16, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Multidisciplinary team diagnosis of IPF or non-IPF fibrotic-ILD
- • Treatment naivety to anti-fibrotic therapy at entry to study
- • Adult ≥18 years \<85
- • Informed consent
- Exclusion Criteria:
- • Forced expiratory volume in 1s/FVC \<0.7,
- • Significant other respiratory pathology including emphysema \>15% on CT (radiologist determined)
- • Evidence of ILD exacerbation at the time of CT
About University Of Exeter
The University of Exeter is a leading research institution in the United Kingdom, renowned for its commitment to advancing knowledge and innovation across various disciplines, including health and medicine. As a clinical trial sponsor, the university leverages its extensive academic expertise and state-of-the-art facilities to conduct rigorous and ethically sound research. The University of Exeter aims to translate scientific findings into practical applications that improve patient outcomes and inform public health strategies, fostering collaboration between researchers, healthcare professionals, and community stakeholders to address critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Exeter, , United Kingdom
Patients applied
Trial Officials
Giles Dixon
Principal Investigator
University of Exeter
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials